Back to News
Market Impact: 0.25
MIRA Advances Phase 2a Study Of Ketamir-2 For Chemotherapy-Linked Neuropathy; Stock Up
Source: Nasdaq
Healthcare & Biotech
MIRA Pharmaceuticals reported progress advancing Ketamir-2 toward a Phase 2a trial for chemotherapy-induced peripheral neuropathy. The clinical-stage development milestone is positive for MIRA's pipeline, though no efficacy data, financial impact, or trial timing was disclosed.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.35
Ticker Sentiment
MIRA0.60
More News
- Amgen (AMGN) Bets on MariTide to Crack $120 Billion Obesity Market
- BTIG cuts Acumen Pharmaceuticals stock price target to $1 on trial results
- Wells Fargo raises Abbvie stock price target to $340 on pipeline
- Wells Fargo raises Regeneron stock price target to $925 on execution
- Deutsche Bank downgrades Novartis stock rating to sell on valuation
- Apple, Marriott International and 3 Stocks to Watch Heading Into Monday
From AllMind Research
- AllMind Platform Feature Updates - Fall 2026
- AI Credit Covenant Monitoring: From Clause to Review
- AI-Led Expert Interviews vs. Transcript Libraries
- State of M&A and Private Markets, June 2026: A $4.9 Trillion Rebound, Underwritten on Money That Never Got Cheaper
- Quartr Alternatives for Institutional Research Teams